Uncategorized
EyeGate Pharmaceuticals reports higher net loss in third quarter
EyeGate Pharmaceuticals reported a $3.377 million net loss in the third quarter, compared with a $1.356 million net loss in the third quarter of 2015, according to a company press release.A phase 3 confirmatory trial of EGP-437 for the treatment of anterior uveitis, a phase 1b/2a trial for the treatment of post-cataract surgery inflammation and pain, as well as the development of EyeGate OBG, an ocular bandage gel, were partly attributed to the higher net loss, the release said.